Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Highlights from ESMO Breast 2024: addressing toxicities in new cancer treatments

Janice Wing-Hang Tsang • 17 May 2024
ESMO Breast 2024
Breast Cancer Antibodies

Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, discusses the key highlights from the 2024 European Society for Medical Oncology (ESMO) Breast meeting, focusing on a comprehensive session about the toxicities of new cancer treatments, including immunotherapy, antibody-drug conjugates (ADCs), and molecular oral agents. The session emphasized proactive patient education and special attention to older adults. This interview took place at the 2024 ESMO Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Janice Wing-Hang Tsang

Metastatic breast cancer updates at ESMO 2025
2:37
Metastatic breast cancer updates at ESMO 2025
Janice Wing-Hang Tsang • 17 Oct 2025
13-year follow up results of the SOFT and TEXT trials in ILC
1:56
13-year follow up results of the SOFT and TEXT trials in ILC
Janice Wing-Hang Tsang • 17 May 2024
Assisted reproductive techniques in patients after BRCA-mutant breast cancer
1:55
Assisted reproductive techniques in patients after BRCA-mutant breast cancer
Janice Wing-Hang Tsang • 17 May 2024
Enhancing patient education in breast cancer treatment
3:25
Enhancing patient education in breast cancer treatment
Janice Wing-Hang Tsang • 21 Oct 2023

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals